Cargando…

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

Detalles Bibliográficos
Autores principales:	Curl, Patti, Vujic, Igor, van ‘t Veer, Laura J., Ortiz-Urda, Susana, Kahn, James G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404367/ https://www.ncbi.nlm.nih.gov/pubmed/25893993 http://dx.doi.org/10.1371/journal.pone.0126988

Ejemplares similares

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2014)

Correction: Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
Publicado: (2015)

Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox
por: Goldenberg, Alina, et al.
Publicado: (2015)

Cutaneous CD56(+) T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma
por: Zheng, Yixuan James, et al.
Publicado: (2018)

Correction: Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF(V600E) mutation
por: García-Silva, Susana, et al.
Publicado: (2019)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Clinical significance of BRAF mutations in metastatic melanoma
por: Chang, David Z, et al.
Publicado: (2004)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Correction to: BRAF Inhibitor Resistance in Meslanoma: Mechanisms and Alternative Therapeutic Strategies
por: Zhong, Jingqin, et al.
Publicado: (2022)

Correction to: RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
por: Lei, Fu Xi, et al.
Publicado: (2019)

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas
por: Posch, Christian, et al.
Publicado: (2018)

Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma
por: McGettigan, Suzanne
Publicado: (2014)

Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
por: Garrisi, Vito Michele, et al.
Publicado: (2014)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

Correction: BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis
Publicado: (2021)

Correction: Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo
por: Posch, Christian, et al.
Publicado: (2016)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma
por: Shelledy, Lindsay, et al.
Publicado: (2015)

Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
por: Swofford, Brenen P., et al.
Publicado: (2017)

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
por: Gouda, M.A., et al.
Publicado: (2021)

Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma
por: Doma, V., et al.
Publicado: (2019)

Correction: Frequent MAGE Mutations in Human Melanoma
por: Caballero, Otavia L., et al.
Publicado: (2010)

Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2023)

Author Correction: Identification of recurrent USP48 and BRAF mutations in Cushing’s disease
por: Chen, Jianhua, et al.
Publicado: (2023)

BRAF Mutation Heterogeneity in Melanoma Lesions
por: SAKAIZAWA, Kaori, et al.
Publicado: (2020)

The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
por: Porcelli, Letizia, et al.
Publicado: (2015)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma
por: Ruiz-Garcia, Erika, et al.
Publicado: (2017)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma
por: Serra, Francesco, et al.
Publicado: (2021)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
por: Mezi, Silvia, et al.
Publicado: (2023)

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
por: Vujic, Igor, et al.
Publicado: (2016)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
por: Han, Shujun, et al.
Publicado: (2018)

Correction: Expression of IL-27 by Tumor Cells in Invasive Cutaneous and Metastatic Melanomas
por: Gonin, Julie, et al.
Publicado: (2013)

Correction: FRIZZLED7 Is Required for Tumor Inititation and Metastatic Growth of Melanoma Cells
por: Tiwary, Shweta, et al.
Publicado: (2017)

NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kcajq64qqpdatn1uacqq91s5e5